In short
Larotrectinib Sulfate, also known as LOXO-101, is an innovative targeted therapy being studied in clinical trials for patients with advanced solid tumors, lymphomas, and leukemias that have specific genetic alterations called TRK fusions. These trials aim to evaluate how well larotrectinib works in shrinking tumors and improving outcomes for patients whose cancers have not responded to standard treatments. The drug works by blocking TRK proteins that drive cancer growth in tumors with NTRK gene fusions.
At a glance
- Drug Name
- Larotrectinib Sulfate (LOXO-101)
- Target
- TRK proteins in cancers with NTRK gene fusions
- Administration
- Oral (tablets/liquid), twice daily; sometimes via NG or G-tube
- Cancer Types
- Advanced solid tumors, lymphomas, leukemias with TRK fusions
- Key Outcomes Measured
- Objective response rate, progression-free survival, overall survival, duration of response
- Safety Monitoring
- Adverse events, focusing on grade 3 or higher toxicities
- Additional Assessments
- Tumor biopsies, blood samples, imaging (CT, MRI, PET scans)
- Special Populations
- Includes pediatric patients in some trials
- Treatment Duration
- Up to 2 years in absence of disease progression or unacceptable toxicity
What is Larotrectinib?
Larotrectinib Sulfate, also known by its brand name Vitrakvi, is a targeted cancer therapy drug. It's also referred to by several other names in scientific literature, including ARRY 470 Sulfate, LOXO 101 Sulfate, and LOXO-101 Sulfate. This medication is part of a new generation of cancer treatments that focus on specific genetic changes in cancer cells rather than attacking all rapidly dividing cells like traditional chemotherapy.
How Does Larotrectinib Work?
Larotrectinib is designed to target a specific genetic alteration in cancer cells. It works by blocking enzymes called TRK (tropomyosin receptor kinase) proteins. These proteins are produced when certain genes, known as NTRK genes, fuse or join with other genes. This fusion can lead to uncontrolled cell growth and cancer. By blocking the TRK proteins, Larotrectinib may stop the growth of tumor cells.
What Conditions Does Larotrectinib Treat?
Larotrectinib is used to treat a variety of cancers that have a specific genetic feature called an NTRK gene fusion. These cancers can occur in different parts of the body and include:
- Solid tumors: These are cancers that form solid masses in the body, such as in the lungs, breast, or colon.
- Locally advanced cancers: These are cancers that have spread from where they started to nearby tissue or lymph nodes.
- Metastatic cancers: These are cancers that have spread to other parts of the body.
- Infantile fibrosarcoma: A rare type of cancer that occurs in infants and young children.
- Central nervous system tumors: Cancers that occur in the brain or spinal cord.
- Relapsed or refractory acute leukemia: Blood cancers that have come back after treatment or do not respond to initial treatment.
It's important to note that Larotrectinib is typically used when the cancer has progressed after other treatments or when there is no satisfactory alternative treatment option.
How is Larotrectinib Administered?
Larotrectinib is taken orally (by mouth) in the form of a pill or liquid. It's usually taken twice a day. In some cases, especially for patients who can't swallow pills, it can be given through a nasogastric tube (a tube that goes through the nose into the stomach) or a gastric tube (a tube that goes directly into the stomach).
The treatment is typically given in cycles, with each cycle lasting 28 days. Patients may continue taking Larotrectinib for up to 26 cycles (about 2 years) as long as the cancer doesn't get worse and the side effects are manageable.
Clinical Trials and Research
Larotrectinib has been and continues to be studied in various clinical trials. These studies aim to understand how well the drug works for different types of cancers and in different patient populations. Some key aspects of these trials include:
- Objective Response Rate (ORR): This measures how many patients' tumors shrink or disappear after treatment. In some trials, researchers are looking at whether Larotrectinib can shrink tumors enough to make surgery possible.
- Duration of Response (DoR): This looks at how long the cancer stays controlled after it responds to treatment.
- Progression-Free Survival (PFS): This measures how long patients live without their cancer getting worse.
- Overall Survival (OS): This looks at how long patients live overall after starting treatment.
- Safety and Side Effects: Researchers are carefully monitoring any side effects or safety concerns related to the medication.
Some trials are also looking at using Larotrectinib before surgery (called neoadjuvant therapy) to see if it can shrink tumors and make surgery easier or more effective.
Potential Side Effects
As with all medications, Larotrectinib can cause side effects. In clinical trials, researchers are carefully monitoring patients for any adverse reactions. Common side effects may include fatigue, nausea, dizziness, and constipation. More serious side effects are possible but less common. It's important for patients to discuss potential side effects with their healthcare provider.
Larotrectinib represents a significant advancement in targeted cancer therapy. By focusing on specific genetic changes in cancer cells, it offers hope for patients with various types of cancers that have not responded to other treatments. As research continues, we may learn even more about how to use this medication effectively to help cancer patients.